Baudax Bio, Inc.
490 Lapp Road
Malvern, Pennsylvania 19355
April 26, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Industrial Applications and Services
100 F Street, NE
Washington, D.C. 20549
Attn: Jane Park and Celeste Murphy
Re: Baudax Bio, Inc.
Registration Statement on Form S-1
SEC File No. 333-271161
Request for Acceleration
Ms. Park:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Baudax Bio, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-2711611), as amended (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 5:15 PM, eastern time, on April 26, 2023, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Goodwin Procter LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Goodwin Procter LLP, by calling Justin Platt at (212) 459-7340.
Please feel free to direct any questions or comments concerning this request to Justin Platt, Esq. of Goodwin Procter LLP at (212) 459-7340.
| BAUDAX BIO, INC. | ||
| By: | /s/ Gerri Henwood | |
| Name: | Gerri Henwood | |
| Title: | President and Chief Executive Officer | |
Cc: Rachael M. Bushey, Goodwin Procter LLP
